Percheron Therapeutics CEO James Garner joined Steve Darling from Proactive to discuss the company’s unique approach to treating Duchenne muscular dystrophy (DMD), a progressive genetic disorder primarily affecting boys and characterized by muscle degeneration.
Current treatments, such as gene therapy and anti-inflammatory medications, often fall short in effectively managing the disease. Percheron’s lead candidate, ATL1102, or avicursen has demonstrated promising results in early pilot studies by helping stabilize disease progression in later-stage patients.
The company is now conducting an international Phase 2B trial to gather more robust data for regulatory review, with initial results anticipated in December 2024. Garner highlighted the urgent need for new and effective therapies for DMD, noting that avicursen's development could significantly improve patients' quality of life.
This approach could offer hope to DMD patients and their families, who often face limited treatment options.